A cross-national study of the persistence of antihypertensive medication use in the elderly

Journal of Hypertension

Volumn 26, Issue 1, 2008, Pages 145-153

  Van Wijk, Boris L G ^a   Shrank, William H ^b   Klungel, Olaf H ^a   Schneeweiss, Sebastian ^b   Brookhart, M Alan ^b   Avorn, Jerry ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adherence; Antihypertensive drugs; Discontinuation; Hypertension; Persistence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DATA BASE; ELDERLY CARE; FEMALE; FOLLOW UP; GERIATRICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; NETHERLANDS; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CANADA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; NETHERLANDS; PATIENT COMPLIANCE; PENNSYLVANIA; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 37349115238     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32826308b4     Document Type: Article

References (48)

1. Ezzati M, Vander Hoorn S, Lawes CMM, Leach R, James WPT, Lopez AD, et al. Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med 2005; 2:e133.
2. Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens 2004; 18:545-551.
3. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-2544.
4. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17.
5. Stephenson J. Noncompliance may cause half of antihypertensive drug "failures". JAMA 1999; 282:313-314.
6. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19:335-341.
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
8. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
9. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al., for the INVEST Investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
10. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
11. Brown MJ, Palmer CR, Castaigne A, De Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to doubleblind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
12. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
13. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279:1458-1462.
14. Diagnosis Related Groups. Atlanta, GA: National Center for Health Statistics, Centers for Disease Controls and Prevention, Department of Health and Human Services. 2006.
15. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". N Engl J Med 1983; 308:1457-1463.
16. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol 1989; 42:937-945.
17. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37:846-857.
18. Miller E, Blatman B, Einarson TR. A survey of population-based drug databases in Canada. Can Med Assoc J 1996; 154:1855-1864.
19. Anderson GM, Kerluke KJ, Pulcins IR, Hertzman C, Barer ML. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Inquiry 1993; 30:199-207.
20. Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension. Arch Intern Med 2001; 161:1873-1879.
21. Williams J, Young W. Inventory of studies on the accuracy of Canadian health administrative databases: technical report. Toronto: Insitute for Clinical Evaluative Sciences (ICES); 1996.
22. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19:607-613.
23. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. Can Med Assoc J 2002; 166:737-745.
24. Nakagawa B, Hudson R. Reference-based pricing. Can Med Assoc J 2000; 162:12; 14; author reply 14, 18..
25. Deaton A. Policy implications of the gradient of health and wealth. Health Aff (Millwood) 2002; 21:13-30.
26. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands, dissertation. Utrecht, the Netherlands: Department of Pharmaco-Epidemiology, Utrecht University; 1993.
27. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46:136-140.
28. Hoek JF, Penninx BW, Ligthart GJ, Ribbe MW. Healthcare for older persons, a country profile: the Netherlands. J Am Geriatr Soc 2000; 48:214-217.
29. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006; 59:11-17.
30. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
31. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
32. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
33. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
34. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263:1653-1657.
35. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455-461.
36. Warburton R. Takeup of income-tested healthcare premium subsidies: evidence and remedies for British Columbia. Can Tax J 2005; 53:1-28.
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-383.
38. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
39. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep 2002; 4:424-433.
40. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23:2101-2107.
41. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166:332-337.
42. Van Wijk BL, Klungel OH, Heerdink ER, De Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004; 22:1831-1837.
43. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2006; CD005182.
44. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Available at: http://www.who.int/chp/knowledge/ publications/adherence_report/en/ Accessed: October 2007.
45. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24:1193-1200.
46. Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004; 20:417-421.
47. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Sapiera GM, Platt R. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332:1125-1131.
48. List of Essential Medicines. Geneva: World Health Organization; 2005. Available at: http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf Accessed: October 2007